A clinical research organization's dataset has been discovered online The documents include Personally Identifiable ...

Q4 2024 Management View CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical advancements in its obesity pipeline, particularly with ...

Drug development is an expensive and high-risk process. The median cost per approved drug can reach up to $2.8 billion, ...

While many sites expressed an interest in sustainability, most lacked the bandwidth to support our data collection efforts. For utilities consumption at the trial site and at other sites (eg, clinical ...

Brad O'Connor, CEO, highlighted the company’s record revenue of $23.9 million for the first half of FY 2025, driven by a 27% growth in clinical trials revenue compared to the prior corresponding ...

In this digital era, Vamsi Upputuri, a leading expert in regulatory automation, explores cutting-edge advancements in ...

CluePoints named as Finalist in 2025 ACDM AwardsThe Company, along with its Research and Development Teams, were shortlisted for continuing its mission of turning artificial intelligence into a force ...

Oncology studies present unique challenges when it comes to participant treatment, resupply, and study management.

Grant funding uncertainty has jeopardized the sustainability of research projects and discouraged researchers.

Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...